Sales Performance - In the first half of 2024, the sales revenue of Pudilan Anti-inflammatory Tablets exceeded 100 million CNY, achieving nearly double-digit growth year-on-year [2] - The sales revenue of Gongxuening Capsules increased by 36% year-on-year [2] - The health product segment achieved a revenue of 3.144 billion CNY, with a net profit of 1.231 billion CNY, and a net profit growth of 1.7% year-on-year [4] - The sales revenue of Yangyuanqing hair care products reached 195 million CNY, with a growth rate of 41% [4] Marketing and Brand Positioning - The online marketing campaign generated approximately 350 million exposures and 2.96 million interactions, attracting over 1.1 million consumers and achieving a GMV growth of 47% year-on-year [2] - Yunnan Baiyao toothpaste maintained its leading market share in the domestic oral care sector, ranking as the top oral care brand during the "618" shopping festival [4] - Yangyuanqing was recognized as the top brand for anti-hair loss shampoo on Tmall during the "618" period [4] Dividend Distribution - In 2023, Yunnan Baiyao's dividend plan was 20.77 CNY per 10 shares, totaling 3.706 billion CNY, which accounted for 90.53% of the net profit [5] - A special dividend of 12.13 CNY per 10 shares is proposed for 2024, with a total amount of 2.164 billion CNY, representing 50.02% of the net profit for the first three quarters of 2024 [6] Future Development Plans - The provincial pharmaceutical company aims to stabilize revenue growth, enhance risk management, and improve operational efficiency [7] - The overall strategic goal is to achieve growth in revenue, profit, and asset scale through a "2+3" strategy from 2024 to 2028, positioning itself as a leading modern pharmaceutical group [8]

Group 1: Investor Relations Activity - The meeting was categorized as a specific object investigation and on-site visit [2] - Participants included representatives from Agricultural Bank of China and Northeast Securities [2] - The meeting took place on January 10, 2025, at the company's headquarters [2] Group 2: Purpose of the Meeting - The main objective was to understand the company's production and operational status [2] - The meeting involved discussions on relevant issues concerning the company's performance [2] Group 3: Attendees - Company representatives included securities affairs representative Li Mengjue and investor relations manager Yang Kexin [2]

Dividend Distribution - In 2023, Yunnan Baiyao's dividend plan was to distribute 20.77 CNY per 10 shares, totaling 3.706 billion CNY, which accounted for 90.53% of the net profit attributable to shareholders [2] - For 2024, the company plans to distribute 12.13 CNY per 10 shares, with a total dividend amount of 2.164 billion CNY, representing 50.02% of the net profit for the first three quarters [2] - Since its listing in 1993, Yunnan Baiyao has distributed dividends for 31 consecutive years, with cumulative cash dividends exceeding 26.6 billion CNY [2] Pharmaceutical Business Performance - In the first half of 2024, sales revenue of Yunnan Baiyao aerosol exceeded 1.2 billion CNY, with a year-on-year growth of over 30% [3] - The pharmaceutical division aims to enhance its brand positioning in pain management and optimize business layout through online and offline integration [3] - The company plans to establish "pain service centers" in community pharmacies to provide initial treatment services and meet diverse pain management needs [3] Oral Care Product Sales - Yunnan Baiyao toothpaste maintained a leading market share in the domestic oral care sector in the first half of 2024 [4] - During the "618" shopping festival, Yunnan Baiyao's oral health brand ranked as the top online oral care brand [4] - The company implemented targeted marketing campaigns to enhance brand recognition and consumer engagement, achieving over 3.6 billion total exposures [5] Channel Development Strategies - The company has established a comprehensive marketing network covering various medical institutions and retail pharmacies across China [6] - Yunnan Baiyao collaborates with over 5,000 leading chain pharmacies and has a strong presence in regions like East China, Hunan, Hubei, and Yunnan [6] - The company is actively expanding its online sales channels through partnerships with major e-commerce platforms and optimizing traditional and emerging retail channels [6]

Group 1: Investor Relations Activity - The investor relations activity included specific object research and media interviews [2] - Participants from the investment side included representatives from Shouyu Yinxin [2] - The meeting took place on January 7, 2025, at the company's headquarters [2] Group 2: Company Overview - The main purpose of the meeting was to understand the company's production and operational status [2] - Company representatives included the securities affairs representative and investor relations management [2]

Sales Performance - In the first half of 2024, the pharmaceutical segment achieved a revenue of 4.069 billion CNY, a year-on-year increase of 9.6% [2] - Sales of the core product, Yunnan Baiyao aerosol, exceeded 1.2 billion CNY, with a growth rate of over 30% [2] - Other traditional Chinese medicine products, such as Pudi Lan anti-inflammatory tablets, surpassed 100 million CNY in sales, achieving nearly double-digit growth [3] - The sales of Gynaecological products, such as Gongxue Ning capsules, increased by 36% year-on-year [3] - The sales of Qi Xue Kang oral liquid exceeded 100 million CNY, while Sanqi Ren honey oral liquid saw a growth of over 80% [3] Marketing and Channel Strategy - The company implemented a "普药千家万户" project to enhance offline distribution and established a short-channel operation model [3] - Online marketing efforts resulted in approximately 350 million exposures and 2.96 million interactions, driving over 1.1 million consumers to e-commerce platforms [3] - The company engaged in a basketball event with 512 teams participating, generating over 290 million views on Douyin [3] Oral Care Products - Yunnan Baiyao toothpaste maintained its leading market share in the domestic oral care sector [4] - During the "618" shopping festival in 2024, Yunnan Baiyao ranked as the top oral care brand across all online platforms [4] - The company has a well-established national sales team for health products, enhancing its market competitiveness [4] Dividend Policy - In 2023, the company announced a cash dividend of 20.77 CNY per 10 shares, totaling 3.706 billion CNY, which accounted for 90.53% of the net profit [6] - A special dividend proposal for 2024 was approved, with a distribution of 12.13 CNY per 10 shares, totaling 2.164 billion CNY, representing 50.02% of the net profit for the first three quarters [6] - Since its listing in 1993, the company has distributed over 26.6 billion CNY in cash dividends over 31 years [6] Strategic Goals - The company aims to achieve growth in revenue, profit, and asset scale through a "2+3" strategic plan from 2024 to 2028 [7][8] - The strategic positioning includes four segments: Traditional Chinese Medicine resources, pharmaceutical products, health products, and pharmaceutical commerce [7][8]

Group 1: Investor Relations Activities - The meeting was categorized as a telephone conference for investor relations activities [2] - Participants included representatives from Dymon Asia and CITIC Securities [2] - The meeting took place on January 8, 2025, at the company's headquarters [2] Group 2: Purpose of the Meeting - The main objective was to understand the company's production and operational status [2] - Discussions included various relevant questions regarding the company's performance [2]

证券代码：000538 证券简称：云南白药 公告编码：2024-61 云南白药集团股份有限公司 关于2024—2028战略规划的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏。 特别提示： 由于战略规划是基于公司现阶段情况制定的发展规划和目标，本公告 中涉及的未来计划、目标等前瞻性陈述，均不构成公司对投资者的实质承诺。 鉴于宏观经济环境、行业发展形势和市场环境的快速变化，根据公司发展需 要，存在对本战略规划作相应调整的可能。敬请投资者注意投资风险。 云南白药集团股份有限公司（以下简称"公司"或"云南白药"）于 2024 年 12 月 27 日召开第十届董事会 2024 年第十二次会议，审议通过《关于云 南白药集团 2024—2028 战略规划的议案》，现将具体内容公告如下： 一、概述 《云南白药集团 2024—2028 战略规划》（以下简称"《战略规划》"） 是指导云南白药未来五年工作计划的纲领性文件，公司按照"问题导向、发展 导向、目标导向"的原则进行编制。主动求变、谋发展、上台阶，将《战略规 划》主题确定为：继往开来，守正创新，超越自我再出发，推动百年白药 ...

股票代码：000538 股票简称：云南白药 公告编号：2024-62 云南白药集团股份有限公司 关于 2025 年度预计日常关联交易的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 一、日常关联交易基本情况 （一）日常关联交易概述 1、云南白药集团股份有限公司（以下简称"公司"）根据 2025 年 度日常经营需要，对包括采购、销售商品等与日常经营相关的其他各项 关联交易进行了合理预计，预计公司 2025 年与上海医药集团股份有限公 司 （ 以 下 简 称 " 上 海 医 药 " ） 发 生 的 日 常 关 联 交 易 合 计 总 额 为 190,000.00 万元，占公司最近一期经审计净资产 3,987,912.20 万元的 4.76%，无需报股东大会审议。截至 2024 年 11 月末，公司 2024 年与上 海医药实际发生日常关联交易总额为 114,070.25 万元，未超过 2024 年经 董事会、股东大会审议通过的额度。 2、本事项已经于 2024 年 12 月 20 日召开的公司独立董事专门会议 2024 年第四次会议审议通过，公司全体独立董事 ...

股票代码：000538 股票简称：云南白药 公告编号：2024-60 云南白药集团股份有限公司 第十届董事会 2024 年第十二次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 云南白药集团股份有限公司（以下简称"公司"或"云南白药"）第十 届董事会 2024 年第十二次会议（以下简称"会议"）于 2024 年 12 月 27 日 以通讯表决的方式召开，本次会议通知于 2024 年 12 月 20 日以书面、邮件 方式发出，应出席董事 11 名，实际出席董事 11 名。本次会议的召集、召开 程序符合《中华人民共和国公司法》《公司章程》的相关规定，会议合法有 效。会议审议通过如下议案： 一、审议通过《关于云南白药集团 2024—2028 战略规划的议案》 具体内容详见公司同日在巨潮资讯网（网址：http://www.cninfo.com.cn） 挂网披露的《关于 2024—2028 战略规划的公告》（公告编号：2024-61）。 表决结果：11 票同意、0 票反对、0 票弃权。 二、审议通过《关于 2025 年度预计日常关联交易的议案》 公司根据 ...

股票代码：000538 股票简称：云南白药 公告编号：2024-63 2、各大金融机构的理财产品，包括银行及其理财子公司、券商、基金 公司等。 云南白药集团股份有限公司 关于 2025 年利用闲置自有资金开展投资理财的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 云南白药集团股份有限公司（以下简称"公司"）第十届董事会 2024 年 第十二次会议（以下简称"会议"）于 2024 年 12 月 27 日以通讯表决方式召 开，会议审议通过了《关于 2025 年利用闲置自有资金开展投资理财的议案》。 具体情况如下： 一、投资情况概述 为确保资金安全及保持合理的流动性，并充分满足公司日常经营和战略 投资的资金需求，同时兼顾公司自有闲置资金收益水平，为公司和股东争取 投资回报，公司拟对2025年理财投资范围、额度等进行合理预计，具体如下： （一）资金来源：公司闲置自有资金。 （二）投资范围： 1、银行的存款类产品，包括大额存单、通知存款、协定存款等。 3、结构性存款、保本收益凭证、货币市场基金、国债逆回购及债券、 债券型基金/资管计划。 4、其它经董事会批准的理 ...